U.S. markets closed

Ultimovacs ASA (7UM.F)

Frankfurt - Frankfurt Delayed Price. Currency in EUR
Add to watchlist
6.07-0.03 (-0.49%)
At close: 9:16AM CEST
Full screen
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close6.24
Open6.07
Bid0.00 x N/A
Ask0.00 x N/A
Day's Range6.07 - 6.07
52 Week Range2.58 - 8.58
Volume448
Avg. Volume7
Market Cap196.313M
Beta (5Y Monthly)N/A
PE Ratio (TTM)N/A
EPS (TTM)-0.40
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
Fair Value is the appropriate price for the shares of a company, based on its earnings and growth rate also interpreted as when P/E Ratio = Growth Rate. Estimated return represents the projected annual return you might expect after purchasing shares in the company and holding them over the default time horizon of 5 years, based on the EPS growth rate that we have projected.
Fair Value
XX.XX
N/A
Research that delivers an independent perspective, consistent methodology and actionable insight
Related Research
    View more
    • Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patients
      Business Wire

      Ultimovacs Announces Positive Topline Results from Phase I Combination Trial Evaluating Universal Cancer Vaccine, UV1, in Malignant Melanoma Patients

      Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), today announced positive topline results from the first cohort of 20 patients in its ongoing US-based Phase I clinical trial evaluating the Company’s lead candidate, UV1, in combination with PD-1 checkpoint inhibitor, pembrolizumab, as a first line treatment in patients with metastatic malignant melanoma. The results confirm achievement of the primary endpoints of safety and tolerability and indicate initial signs of clinical response.

    • Ultimovacs ASA Announces Completion of Patient Enrollment in Phase I Trial in Malignant Melanoma
      Business Wire

      Ultimovacs ASA Announces Completion of Patient Enrollment in Phase I Trial in Malignant Melanoma

      Ultimovacs ASA ("Ultimovacs", ticker ULTIMO), a pharmaceutical company developing novel immunotherapies against cancer, announced today that patient enrollment has been completed in the ongoing US-based Phase I clinical trial testing Ultimovacs’ lead candidate, UV1, in combination with pembrolizumab as first line treatment in patients with metastatic malignant melanoma. The study was designed to assess the safety and tolerability of UV1 combined with checkpoint inhibitor pembrolizumab and to explore initial signs of clinical response.